Dermatology

Although a majority of pediatricians are aware of the guidelines, less than one-third of survey respondents report full implementation.

The FDA is looking for more information regarding aspects of the chemistry, manufacturing, and controls process for the drug-device combination

Subcutaneous injections of nemolizumab in addition to topical agents result in a greater reduction in pruritus than placebo plus topical agents.

Patients with acne who receive isotretinoin treatment can expect a four- to five-fold improvement from baseline to follow-up in quality of life.

The FDA is allowing the pen to be used for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) patients at least 12 years old.

A dermatologist and clinical associate professor of dermatology discusses implementing telehealth in dermatology practices.

Currently, the use of minocycline is limited orally due to some systemic side effects.

The newest indication for the add-on biologic grants it use in children aged 6-11 years old with moderate to severe, uncontrolled atopic dermatitis.

Since the beginning of the COVID-19 pandemic most non-urgent medical appointments have been conducted using telehealth.

With the majority of the scientific research community focused, a COVID-19 vaccine could be on the horizon.

While recent data regarding remdesivir has been positive, there is still a need for medications in pill form to treat COVID-19 infections.

The dermatologist fields questions on possible symptoms and signs of infection that his colleagues have observed.

The Florida-based clinician shares perspective and insight into what should be prioritized or revised in specialty care.

Investigators found 30 mg of apremilast results in a significant reduction in plaque psoriasis patients.

An assessment of survey data show patients with severe depressive or psychological symptoms are more likely to be dissatisfied with their dermatologist.

An expert describes how telehealth can be used during the pandemic.

A dermatologist discusses how to care for patients with psoriasis during the COVID-19 pandemic.

Enjoy our archived discussion between 4 experts on how their specialty is most affected by the pandemic.

A systematic review and meta-analysis show the systemic therapies, as well as a couple investigational biologics, may be superior.

The treatment was initially approved for adults >18 years old.

The free webinar, "Derm Clinical Updates: Keeping Up with COVID-19," will feature a four-expert panel fielding topics on therapies, immunocompromised patients, telemedicine, surgery, and more.

The IL-17A-targeting biologic has now been indicated for pediatric plaque psoriasis—marking its fourth indication for patients with chronic diseases.

Clinical investigator and allergist Jonathan Corren, MD, shares insight on the TSLP inhibitor.

New phase 3 IMMhance findings show durable, sustained effect of the IL-23 inhibitor on a 12-week dose regimen.

New pivotal phase 3 findings support an upcoming sBLA for the IL4 and IL13-targeting agent.